AdipoGen Life Sciences

Ac-Trp-Leu-Ala-AMC

CHF 70.00

In stock

AG-CP3-0035-M0011 mgCHF 70.00

AG-CP3-0035-M0055 mgCHF 280.00

More Information
Product Details
Synonyms	Ac-WLA-AMC; Proteasome Substrate
Product Type	Chemical
Properties
Formula	C₃₂H₃₇N₅O₆
MW	587.7
Sequence	Acetyl-Trp-Leu-Ala-7-amido-4-methylcoumarin
CAS	1104011-59-7
Purity Chemicals	≥98% (HPLC)
Appearance	Lyophilized powder.
Solubility	Soluble in DMSO.
Identity	Determined by MS
Other Product Data	Use: After preparing a stock solution in DMSO (≥10mM) store product at -20°C to -80°C. It is recommended to make multiple aliquots after the first thaw to ensure best performance. Chymotrypsin-like activity can be measured using a typical working concentration range from 10-50µM.
InChi Key	PIJMRHCPKXLMIS-DOYMOWJKSA-N
Smiles	CC(C1=CC=C(C=C1O2)NC([C@H](C)NC([C@H](CC(C)C)NC([C@@H](NC(C)=O)CC3=CNC4=CC=CC=C34)=O)=O)=O)=CC2=O
Shipping and Handling
Shipping	AMBIENT
Short Term Storage	+4°C
Long Term Storage	-20°C
Handling Advice	Avoid freeze/thaw cycles. Protect from light.
Use/Stability	Stable for at least 1 year after receipt when stored at -20°C.
Documents
MSDS	Download PDF
Product Specification Sheet
Datasheet	Download PDF

Description

Fluorogenic peptide substrate for measuring chymotrypsin-like activity of the 20S proteasome. This substrate is hydrolyzed by the β5-subunit of the 20S proteasome to generate detectable fluorescence. 20S Proteasome enzyme requires activation with 0.035% SDS in the assay buffer.
Excitation: 345nm. Emission: 445nm.
Specific substrate to the constitutive proteasome, not hydrolyzed efficiently by the immunoproteasome.
This substrate is useful for inhibitor screening and kinetic analysis.

Product References

Characterization of a new series of non-covalent proteasome inhibitors with exquisite potency and selectivity for the 20S β5-subunit: C. Blackburn, et al.; Biochem. J. 430, 461 (2010)
The immunoproteasome as a therapeutic target for hematological malignancies: Z. Miller, et al.; Curr. Can. Drug Targets 14, 537 (2014)
Immunoproteasome-selective inhibitors: a promising strategy to treat hematologic malignancies, autoimmune and inflammatory diseases: R. Ettari, et al.; Curr. Med. Chem. 23, 1217 (2016)

Call	+41 61 926 6040
Fax	+41 61 926 6049